Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 1, 2011

Oxford Medical Diagnostics Obtains $1.61M Financing

  • Oxford Medical Diagnostics (OMD), the developer of breath-based tests for metabolic and infectious diseases, reports raising £981,000 (roughly $1.61 million). The funding will be used in the development of its device for the diagnosis and monitoring of type 1 and 2 diabetes.

    By next year, the company aims to bring to market a point-of-care diagnostic that detects the volatile gas acetone, which is reportedly a known marker for both types of diabetes. This test is based on OMD’s CEAS (cavity enhanced absorption spectroscopy) and PES (plasma emission spectroscopy) technologies, and the company is also working on diagnostics for infectious diseases.

    OMD says that it has raised £2.2 million to date. The company also generates revenue from its gas analysis service segment. Besides the CEAS and PES platforms, OMD’s technologies included broadband CEAS. The firm says that it recently signed an R&D agreement with gas analyst specialist Michell Instruments of Ely.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »